Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review

Metabolism: Clinical and Experimental

Volumn 65, Issue 9, 2016, Pages 1297-1306

  Polyzos, Stergios A ^a   Mantzoros, Christos S ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adiponectin; Nonalcoholic steatohepatitis; Pioglitazone; Rosiglitazone; Thiazolidinediones

Indexed keywords

ADIPONECTIN; CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTOXIFYLLINE; PIOGLITAZONE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOQ PROTEIN, HUMAN;

ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DISEASE ACTIVITY SCORE; DIZZINESS; DRUG RESPONSE; FATIGUE; HEADACHE; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; IRITIS; LEG SWELLING; LIVER FUNCTION TEST; LIVER HISTOLOGY; MUSCLE CRAMP; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN; ADULT; ANIMAL; META ANALYSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADIPONECTIN; ADULT; ANIMALS; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; THIAZOLIDINEDIONES;

EID: 84973518494     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.05.013     Document Type: Review

References (53)

1. Y Fazel, AB Koenig, M Sayiner, ZD Goodman, and ZM Younossi Epidemiology and natural history of nonalcoholic fatty liver disease Metabolism 2016 10.1016/j.metabol.2016.01.012
2. SA Polyzos, J Kountouras, and C Zavos Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines Curr Mol Med 72 2009 299 314
3. ME Rinella Nonalcoholic fatty liver disease: a systematic review JAMA 313 2015 2263 2273
4. N Chalasani, Z Younossi, JE Lavine, AM Diehl, EM Brunt, K Cusi, and et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Hepatology 55 2012 2005 2023
5. SA Polyzos, J Kountouras, and CS Mantzoros Adipokines in nonalcoholic fatty liver disease Metabolism 2016 10.1016/j.metabol.2015.11.006
6. SA Polyzos, J Kountouras, C Zavos, and E Tsiaousi The role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease Diabetes Obes Metab 12 2010 365 383
7. SA Polyzos, KA Toulis, DG Goulis, C Zavos, and J Kountouras Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis Metabolism 60 2011 313 326
8. SA Polyzos, J Kountouras, and C Zavos Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis Hepatol Res 40 2010 446 447
9. SA Polyzos, J Kountouras, and C Zavos Adiponectin in non-alcoholic fatty liver disease treatment: therapeutic perspectives and unresolved dilemmas Int J Clin Pract 65 2011 373 374
10. A Xu, Y Wang, H Keshaw, LY Xu, KS Lam, and GJ Cooper The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice J Clin Invest 112 2003 91 100
11. J Fukushima, Y Kamada, H Matsumoto, Y Yoshida, H Ezaki, T Takemura, and et al. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization Hepatol Res 39 2009 724 738
12. F Simpson, and JP Whitehead Adiponectin-it's all about the modifications Int J Biochem Cell Biol 42 2010 785 788
13. S Sauer Ligands for the nuclear peroxisome proliferator-activated receptor gamma Trends Pharmacol Sci 36 2015 688 704
14. SA Polyzos, J Kountouras, C Zavos, and G Deretzi Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease J Clin Gastroenterol 46 2012 272 284
15. S Singh, R Khera, AM Allen, MH Murad, and R Loomba Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis Hepatology 62 2015 1417 1432
16. G Musso, M Cassader, F Rosina, and R Gambino Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials Diabetologia 55 2012 885 904
17. SE Mahady, AC Webster, S Walker, A Sanyal, and J George The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis J Hepatol 55 2011 1383 1390
18. D Moher, A Liberati, J Tetzlaff, and DG Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269
19. DF Stroup, JA Berlin, SC Morton, I Olkin, GD Williamson, D Rennie, and et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group JAMA 283 2000 2008 2012
20. KQ Cui, XW Zhao, Y Zhang, XH Kang, J Meng, and XL Chen Efficacy of rosiglitazone in treatment of nonalcoholic fatty liver disease and its relations with adiponectin World Chin J Digestology 14 2006 1326 1329
21. AK Gupta, GA Bray, FL Greenway, CK Martin, WD Johnson, and SR Smith Pioglitazone, but not metformin, reduces liver fat in type-2 diabetes mellitus independent of weight changes J Diabetes Complications 24 2010 289 296
22. C Zhu, H Zhou, Y Han, L Ling, and G Huang Application of adiponectin, TNF-α and ferrtin in type 2 diabetes with intrahepatic lipid infiltration Nuclear Techniques 31 2008 356 359
23. L Yang, MQ Song, QL Zhang, L Shou, SF Zang, and YL Yang Effect of piglitazone and metformin on retinol-binding protein-4 and adiponectin in patients with type 2 diabetes mellitus complicated with non-alcohol fatty acid liver diseases Zhongguo Yi Xue Ke Xue Yuan Xue Bao 36 2014 309 312
24. M Saryusz-Wolska, E Szymanska-Garbacz, M Jablkowski, J Bialkowska, M Pawlowski, E Kwiecinska, and et al. Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease Pol Arch Med Wewn 121 2011 61 66
25. GP Aithal, JA Thomas, PV Kaye, A Lawson, SD Ryder, I Spendlove, and et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis Gastroenterology 135 2008 1176 1184
26. A Gastaldelli, SA Harrison, R Belfort-Aguilar, LJ Hardies, B Balas, S Schenker, and et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis Hepatology 50 2009 1087 1093
27. A Gastaldelli, S Harrison, R Belfort-Aguiar, J Hardies, B Balas, S Schenker, and et al. Pioglitazone in the treatment of NASH: the role of adiponectin Aliment Pharmacol Ther 32 2010 769 775
28. G Lutchman, A Modi, DE Kleiner, K Promrat, T Heller, M Ghany, and et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis Hepatology 46 2007 424 429
29. R Belfort, SA Harrison, K Brown, C Darland, J Finch, J Hardies, and et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med 355 2006 2297 2307
30. G Lutchman, K Promrat, DE Kleiner, T Heller, MG Ghany, JA Yanovski, and et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement Clin Gastroenterol Hepatol 4 2006 1048 1052
31. V Ratziu, P Giral, S Jacqueminet, F Charlotte, A Hartemann-Heurtier, L Serfaty, and et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial Gastroenterology 135 2008 100 110
32. BC Sharma, A Kumar, V Garg, RS Reddy, P Sakhuja, and SK Sarin A randomized controlled trial comparing efficacy of pentoxifylline and pioglitazone on metabolic factors and liver histology in patients with non-alcoholic steatohepatitis J Clin Exp Hepatol 2 2012 333 337
33. EM Brunt, CG Janney, AM Di Bisceglie, BA Neuschwander-Tetri, and BR Bacon Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions Am J Gastroenterol 94 1999 2467 2474
34. DE Kleiner, EM Brunt, NM Van, C Behling, MJ Contos, OW Cummings, and et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
35. K Promrat, G Lutchman, GI Uwaifo, RJ Freedman, A Soza, T Heller, and et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis Hepatology 39 2004 188 196
36. P Angulo, DE Kleiner, S Dam-Larsen, LA Adams, ES Bjornsson, P Charatcharoenwitthaya, and et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease Gastroenterology 149 2015 389 397
37. DM Nathan Diabetes: Advances in Diagnosis and Treatment JAMA 314 2015 1052 1062
38. TN Dunn, T Akiyama, HW Lee, JB Kim, TA Knotts, SR Smith, and et al. Evaluation of the synuclein-gamma (SNCG) gene as a PPARgamma target in murine adipocytes, dorsal root ganglia somatosensory neurons, and human adipose tissue PLoS One 10 2015 e0115830
39. K Imajo, K Fujita, M Yoneda, Y Nozaki, Y Ogawa, Y Shinohara, and et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling Cell Metab 16 2012 44 54
40. SA Polyzos, J Kountouras, and CS Mantzoros Leptin in nonalcoholic fatty liver disease: a narrative review Metabolism 64 2015 60 78
41. SA Polyzos, J Kountouras, C Zavos, and G Deretzi The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of literature J Clin Gastroenterol 45 2011 50 54
42. SA Polyzos, KN Aronis, J Kountouras, DD Raptis, MF Vasiloglou, and CS Mantzoros Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis Diabetologia 59 2015 30 43
43. RI Pereira, JW Leitner, C Erickson, and B Draznin Pioglitazone acutely stimulates adiponectin secretion from mouse and human adipocytes via activation of the phosphatidylinositol 3'-kinase Life Sci 83 2008 638 643
44. JM Tishinsky, DW Ma, and LE Robinson Eicosapentaenoic acid and rosiglitazone increase adiponectin in an additive and PPARgamma-dependent manner in human adipocytes Obesity 19 2011 262 268
45. LS Higgins, and CS Mantzoros The development of INT131 as a Selective PPARgamma Modulator: approach to a safer insulin sensitizer PPAR Res 2008 2008 936906
46. SE Nissen, and K Wolski Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality Arch Intern Med 170 2010 1191 1201
47. JD Lewis, A Ferrara, T Peng, M Hedderson, WB Bilker, CP Quesenberry Jr., and et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study Diabetes Care 34 2011 916 922
48. FL Dunn, LS Higgins, J Fredrickson, and AM DePaoli Selective modulation of PPARgamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with type 2 diabetes J Diabetes Complications 25 2011 151 158
49. AM DePaoli, LS Higgins, RR Henry, C Mantzoros, and FL Dunn Can a selective PPARgamma modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care 37 2014 1918 1923
50. S Liu, HJ Wu, ZQ Zhang, Q Chen, B Liu, JP Wu, and et al. The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats Eur J Pharmacol 650 2011 384 389
51. YM Nan, F Han, LB Kong, SX Zhao, RQ Wang, WJ Wu, and et al. Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice Scand J Gastroenterol 46 2011 358 369
52. F Nascimbeni, J Aron-Wisnewsky, R Pais, J Tordjman, C Poitou, F Charlotte, and et al. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease BMJ Open Gastro 3 2016 e000075
53. M Egger, P Juni, C Bartlett, F Holenstein, and J Sterne How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study Health Technol Assess 7 2003 1 76